Home LiteratureArticle Details
PMID: 20538373 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Neurobiology of aging ·Vol. 31 ·No. 8 ·2010-08-00 ·Pages 1263-74

Caroli A, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative

Abstract

The aim of this study was to investigate the dynamics of four of the most validated biomarkers for Alzheimer's disease (AD), cerebro-spinal fluid (CSF) Abeta 1-42, tau, hippocampal volume, and FDG-PET, in patients at different stage of AD. Two hundred twenty-nine cognitively healthy subjects, 154 mild cognitive impairment (MCI) patients converted to AD, and 193 (95 early and 98 late) AD patients were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For each biomarker, individual values were Z-transformed and plotted against ADAS-cog scores, and sigmoid and linear fits were compared. For most biomarkers the sigmoid model fitted data significantly better than the linear model. Abeta 1-42 time course followed a steep curve, stabilizing early in the disease course. CSF tau and hippocampal volume changed later showing similar monotonous trends, reflecting disease progression. Hippocampal loss trend was steeper and occurred earlier in time in APOE epsilon4 carriers than in non-carriers. FDG-PET started changing early in time and likely followed a linear decline. In conclusion, this study provides the first evidence in favor of the dynamic biomarker model which has recently been proposed.

MeSH Terms
Aged Aged, 80 and over Alzheimer Disease/cerebrospinal fluid,diagnosis,metabolism Amyloid beta-Peptides/cerebrospinal fluid Apolipoprotein E4/cerebrospinal fluid Biomarkers/cerebrospinal fluid Cohort Studies Female Fluorodeoxyglucose F18 Follow-Up Studies Genetic Carrier Screening Glucose-6-Phosphate/analogs & derivatives Hippocampus/diagnostic imaging,metabolism,pathology Humans Longitudinal Studies Male Neurobiology/methods,trends Organ Size Peptide Fragments/cerebrospinal fluid Positron-Emission Tomography/methods Prospective Studies tau Proteins/cerebrospinal fluid
Chemicals
Amyloid beta-Peptides Apolipoprotein E4 Biomarkers Peptide Fragments amyloid beta-protein (1-42) tau Proteins Fluorodeoxyglucose F18 2-fluoro-2-deoxyglucose-6-phosphate Glucose-6-Phosphate
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Caroli A
LENITEM Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS S. Giovanni di Dio-FBF, Brescia, Italy. [email protected]
Frisoni G B
Alzheimer's Disease Neuroimaging Initiative
References (52)
52 references, click to expand
  1. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):3035-41 PMID: 17012293
  2. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Arch Neurol. 2003 Dec;60(12):1696-702 PMID: 14676043
  3. Trajectories of brain loss in aging and the development of cognitive impairment.
    Neurology. 2008 Mar 11;70(11):828-33 PMID: 18046010
  4. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.
    Lancet Neurol. 2006 Oct;5(10):828-34 PMID: 16987729
  5. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.
    Brain. 2009 Apr;132(Pt 4):1067-77 PMID: 19251758
  6. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
    N Engl J Med. 1996 Mar 21;334(12):752-8 PMID: 8592548
  7. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
    Ann Neurol. 1995 Oct;38(4):649-52 PMID: 7574462
  8. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study.
    Neurology. 2002 May 28;58(10):1476-82 PMID: 12034782
  9. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Brain. 2009 May;132(Pt 5):1355-65 PMID: 19339253
  10. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease.
    Ann Neurol. 1998 Aug;44(2):288-91 PMID: 9708558
  11. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
    Mol Chem Neuropathol. 1995 Dec;26(3):231-45 PMID: 8748926
  12. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.
    Neurology. 2009 Jul 28;73(4):287-93 PMID: 19636048
  13. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.
    Neurology. 2004 Mar 23;62(6):925-31 PMID: 15037694
  14. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  15. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Alzheimers Dement. 2008 Jan;4(1):38-48 PMID: 18631949
  16. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  17. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Brain. 2008 Jun;131(Pt 6):1630-45 PMID: 18339640
  18. Changes in premorbid brain volume predict Alzheimer's disease pathology.
    Neurology. 2003 Aug 26;61(4):487-92 PMID: 12939422
  19. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
    Clin Chem. 2005 Feb;51(2):336-45 PMID: 15563479
  20. Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia.
    J Magn Reson Imaging. 2002 Sep;16(3):305-10 PMID: 12205587
  21. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia.
    Ann Neurol. 2005 Jun;57(6):896-903 PMID: 15929035
  22. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
    J Neurosci. 2005 Aug 24;25(34):7709-17 PMID: 16120771
  23. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  24. The clinical use of structural MRI in Alzheimer disease.
    Nat Rev Neurol. 2010 Feb;6(2):67-77 PMID: 20139996
  25. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Ann Neurol. 2006 Mar;59(3):512-9 PMID: 16372280
  26. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  27. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.
    Neurology. 2000 Aug 22;55(4):484-89 PMID: 10953178
  28. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Ann Neurol. 2009 Apr;65(4):403-13 PMID: 19296504
  29. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
    Neurology. 2010 Jan 19;74(3):201-9 PMID: 20042704
  30. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
    Eur J Nucl Med Mol Imaging. 2009 May;36(5):811-22 PMID: 19142633
  31. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
    Ann Neurol. 2010 Mar;67(3):317-24 PMID: 20373343
  32. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease.
    Neuroscience. 2000;95(3):721-5 PMID: 10670438
  33. Volumetric transformation of brain anatomy.
    IEEE Trans Med Imaging. 1997 Dec;16(6):864-77 PMID: 9533586
  34. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.
    Nat Rev Drug Discov. 2007 Apr;6(4):295-303 PMID: 17347655
  35. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):439-42 PMID: 16306153
  36. Atrophy rates accelerate in amnestic mild cognitive impairment.
    Neurology. 2008 May 6;70(19 Pt 2):1740-52 PMID: 18032747
  37. FDG PET imaging in patients with pathologically verified dementia.
    J Nucl Med. 2000 Nov;41(11):1920-8 PMID: 11079505
  38. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Neurology. 2007 Feb 13;68(7):501-8 PMID: 17065593
  39. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Arch Neurol. 2009 Mar;66(3):382-9 PMID: 19273758
  40. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
    Neurology. 2007 Aug 28;69(9):871-7 PMID: 17724289
  41. Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance?
    J Insect Sci. 2003;3:34 PMID: 15841249
  42. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
    Ann Neurol. 2010 Mar;67(3):308-16 PMID: 20373342
  43. Relationships between biomarkers in aging and dementia.
    Neurology. 2009 Oct 13;73(15):1193-9 PMID: 19822868
  44. A new rating scale for Alzheimer's disease.
    Am J Psychiatry. 1984 Nov;141(11):1356-64 PMID: 6496779
  45. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
    JAMA. 1995 Mar 22-29;273(12):942-7 PMID: 7884953
  46. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Neurobiol Aging. 2008 May;29(5):669-75 PMID: 17208336
  47. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study.
    Lancet. 2003 Oct 4;362(9390):1121-2 PMID: 14550701
  48. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
    Ann Neurol. 1997 Jul;42(1):85-94 PMID: 9225689
  49. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
    Lancet Neurol. 2010 Jan;9(1):119-28 PMID: 20083042
  50. Imaging beta-amyloid burden in aging and dementia.
    Neurology. 2007 May 15;68(20):1718-25 PMID: 17502554
  51. In vivo mapping of amyloid toxicity in Alzheimer disease.
    Neurology. 2009 Apr 28;72(17):1504-11 PMID: 19398705
  52. Brain imaging evidence of preclinical Alzheimer's disease in normal aging.
    Ann Neurol. 2006 Apr;59(4):673-81 PMID: 16470518
Article Info
Journal
Neurobiology of aging
Abbr.
Neurobiol Aging
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2010.04.024
Email
[email protected]
Published
2010-08-00
Epub
2010-00-11
Pages
1263-74
Language
English
Region
United States
NLM ID
8100437
PMCID
PMC3467365
Subset
IM
Grants
NIA NIH HHS · K01 AG030514 · United States
NIA NIH HHS · P30 AG010129 · United States
NIA NIH HHS · P30 AG010129-20 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U19 AG010483 · United States
External Links
PubMed source DOI: 10.1016/j.neurobiolaging.2010.04.024 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2